Humanigen Inc (HGENQ)

[cowtown jay]

I'm looking forward to how prospective partners may use lenzilumab. For instance, I see that Novavax states they, "Demonstrated our variant strain change capabilities, updating our vaccine to the XBB.1.5 variant for the 2023-2024 vaccination season." Was their ability to accommodate variant strain changes accomplished by enhancing their vaccine with our variant-agnostic lenz?

see pg 4/162 "COVID-19 Clinical and Strain Change"
https://www.sec.gov/Archives/edgar/data/1000694/000100069424000026/novavax2023annualreport-fi.pdf

Also, I'm particularly interested in what role lenz could play in treating or preventing malaria.

"Based on the conclusions reached in the aforementioned studies, we gather that cytokines are important modulators of the immune response in malaria. Dysregulation of the cytokine network in severe malaria is linked to parasite and host factor variations. We have found that many of the cytokines involved in malaria (TNF-a, IFN-?, IL-4, and IL-10) play a double role, as a friend or as an enemy. Proinflammatory cytokines control parasite multiplication and promote parasite clearance. However, elevated levels of proinflammatory cytokines such as TNF-a, IL-6, or IL-8 may be markers of severe malaria. TGF-ß is probably the most important regulatory cytokine that limits the inflammatory process in malaria. Maintaining a balance between proinflammatory and anti-inflammatory cytokines is essential, and disrupting this molecular harmony can lead to unfavorable disease evolution. A better understanding on the cytokine's involvement in malaria pathogenesis could provide the basis for the discovery of novel diagnostic markers and indicators of disease progression and severity, as well as the foundation for the development of new malaria vaccines."

See the Conclusions:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592744/#:~:text=Proinflammatory%20cytokines%20control%20parasite%20multiplication,the%20inflammatory%20process%20in%20malaria.

Prospective partner Sanofi's Global Health Unit plans to, "...provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that end the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered essential by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas including diabetes, cardiovascular disease, tuberculosis, malaria and cancer."

See pg 11, "Corporate Social Responsibility update at the end of the Q1 2024"

https://www.sec.gov/Archives/edgar/data/1121404/000112140424000011/pressreleaseq12024english.htm

Sanofi's product pipeline also includes objectives for treating other indications, such as asthma, which could also be an application for lenz.

I think these are exciting times for Humanigen, and I look forward to my open sell order being filled at $200, in the short squeeze we will have when management recalls their loaned shares.